In vivo pharmacodynamic evaluation of omadacycline (PTK 0796) against Streptococcus pneumoniae in the murine pneumonia model

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 5, 2017, Pages

  Lepak, Alexander J ^a   Zhao, Miao ^a,c   Marchillo, Karen ^c   VanHecker, Jamie ^c   Andes, David R ^a,b,c  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c WILLIAM S MIDDLETON MEMORIAL VETERANS HOSPITAL   (United States)

Author keywords

Omadacycline; Pharmacodynamics; Pneumonia

Indexed keywords

ERYTHROMYCIN; MINOCYCLINE; OMADACYCLINE; TIGECYCLINE; ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG PENETRATION; DRUG POTENCY; ELIMINATION HALF-LIFE; EPITHELIAL LINING FLUID; EVALUATION STUDY; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMIC PARAMETERS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; ANIMAL; ANTIBIOTIC RESISTANCE; DISEASE MODEL; DRUG EFFECTS; FEMALE; INSTITUTE FOR CANCER RESEARCH MOUSE; MICROBIAL SENSITIVITY TEST;

ANIMALS; ANTI-BACTERIAL AGENTS; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, BACTERIAL; FEMALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, PNEUMOCOCCAL; STREPTOCOCCUS PNEUMONIAE; TETRACYCLINES;

EID: 85018187871     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02368-16     Document Type: Article

References (26)

1. GBD Study 2013 Collaborators. 2015. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 385:117-171. https://doi.org/10.1016/S0140-6736 (14)61682-2.
2. Drijkoningen JJ, Rohde GG. 2014. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect 20(Suppl 5):S45-S51. https://doi.org/10.1111/1469-0691.12461.
3. Howard LS, Sillis M, Pasteur MC, Kamath AV, Harrison BD. 2005. Microbiological profile of community-acquired pneumonia in adults over the last 20 years. J Infect 50:107-113. https://doi.org/10.1016/j.jinf.2004.05.003.
4. Welte T, Torres A, Nathwani D. 2012. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax 67: 71-79. https://doi.org/10.1136/thx.2009.129502.
5. Jenkins SG, Farrell DJ. 2009. Increase in pneumococcus macrolide resistance, United States. Emerg Infect Dis 15:1260-1264. https://doi.org/10.3201/eid1508.081187.
6. Jones RN, Sader HS, Mendes RE, Flamm RK. 2013. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). Diagn Microbiol Infect Dis 75: 107-109. https://doi.org/10.1016/j.diagmicrobio.2012.08.024.
7. Tillotson GS. 2016. FDA and the safe and appropriate antibiotic use of fluoroquinolones. Lancet Infect Dis 16:e11-12. https://doi.org/10.1016/S1473-3099(16)00051-7.
8. Aschenbrenner DS. 2016. The FDA revises boxed warning for fluoroquinolones-again. Am J Nurs 116:22-23. https://doi.org/10.1097/01.NAJ.0000494687.10004.61.
9. Honeyman L, Ismail M, Nelson ML, Bhatia B, Bowser TE, Chen J, Mechiche R, Ohemeng K, Verma AK, Cannon EP, Macone A, Tanaka SK, Levy S. 2015. Structure-activity relationship of the aminomethylcyclines and the discovery of omadacycline. Antimicrob Agents Chemother 59: 7044-7053. https://doi.org/10.1128/AAC.01536-15.
10. Macone AB, Caruso BK, Leahy RG, Donatelli J, Weir S, Draper MP, Tanaka SK, Levy SB. 2014. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother 58:1127-1135. https://doi.org/10.1128/AAC.01242-13.
11. Villano S, Steenbergen J, Loh E. 2016. Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections. Future Microbiol 11:1421-1434. https://doi.org/10.2217/fmb-2016-0100.
12. Draper MP, Weir S, Macone A, Donatelli J, Trieber CA, Tanaka SK, Levy SB. 2014. Mechanism of action of the novel aminomethylcycline antibiotic omadacycline. Antimicrob Agents Chemother 58:1279-1283. https://doi.org/10.1128/AAC.01066-13.
13. Tanaka SK, Steenbergen J, Villano S. 2016. Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Bioorg Med Chem 24:6409-6419. https://doi.org/10.1016/j.bmc.2016.07.029.
14. Agwuh KN, MacGowan A. 2006. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58:256-265. https://doi.org/10.1093/jac/dkl224.
15. Andes D, Craig W. 2007. Pharmacokinetics and pharmacodynamics of tetracyclines, p 267-278. In Nightingale CH, Ambrose PG, Drusano GL, Murakawa T (ed), Antimicrobial pharmacodynamics in theory and clinical practice, 2nd ed. Informa Healthcare USA, New York, NY.
16. van Ogtrop ML, Andes D, Stamstad TJ, Conklin B, Weiss WJ, Craig WA, Vesga O. 2000. In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gramnegative bacteria. Antimicrob Agents Chemother 44:943-949. https://doi.org/10.1128/AAC.44.4.943-949.2000.
17. Christianson J, Andes D, Craig W. 2001. Magnitude of the 24-h AUC/MIC required for efficacy of doxycycline (doxy) against Streptococcus pneumoniae (SP) in a murine thigh-infection model, abstr 475. 39th Infectious Diseases Society of America Annual Meeting. Infectious Disease Society of America, San Francisco, CA.
18. Crandon JL, Banevicius MA, Nicolau DP. 2009. Pharmacodynamics of tigecycline against phenotypically diverse Staphylococcus aureus isolates in a murine thigh model. Antimicrob Agents Chemother 53:1165-1169. https://doi.org/10.1128/AAC.00647-08.
19. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP. 2009. Pharmacodynamic profile of tigecycline against methicillin-resistant Staphylococcus aureus in an experimental pneumonia model. Antimicrob Agents Chemother 53:5060-5063. https://doi.org/10.1128/AAC.00985-09.
20. Nicasio AM, Crandon JL, Nicolau DP. 2009. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 53: 2756-2761. https://doi.org/10.1128/AAC.01678-08.
21. Meagher AK, Passarell JA, Cirincione BB, Van Wart SA, Liolios K, Babinchak T, Ellis-Grosse EJ, Ambrose PG. 2007. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skinstructure infections. Antimicrob Agents Chemother 51:1939-1945. https://doi.org/10.1128/AAC.01084-06.
22. Rubino CM, Bhavnani SM, Forrest A, Dukart G, Dartois N, Cooper A, Korth-Bradley J, Ambrose PG. 2012. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia. Antimicrob Agents Chemother 56:130-136. https://doi.org/10.1128/AAC.00277-10.
23. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard, 9th ed. Document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.
24. National Research Council. 1996. Guide for the care and use of laboratory animals. National Academies Press, Washington, DC.
25. Rennard SI, Basset G, Lecossier D, O'Donnell KM, Pinkston P, Martin PG, Crystal RG. 1986. Estimation of volume of epithelial lining fluid recovered by lavage using urea as marker of dilution. J Appl Physiol 60:532-538.
26. Chaturvedi P, Esposito C, Koroma J, Cannon EP, Tanaka SK. 2003. In vitro assessment of plasma protein binding and metabolic stability of PTK.0796, abstr 2675. 43rd Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC.